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A Mutation of b-Actin That Alters Depolymerization Dynamics Is
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Actin, one of the major ﬁlamentous cytoskeletal molecules, is involved in a variety of cellular functions. Whereas
an association between muscle actin mutations and skeletal and cardiac myopathies has been well documented,
reports of human disease arising from mutations of nonmuscle actin genes have been rare. We have identiﬁed a
missense point mutation in the gene coding for b-actin that results in an arginine-to-tryptophan substitution at
position 183. The disease phenotype includes developmental midline malformations, sensory hearing loss, and a
delayed-onset generalized dystonia syndrome in monozygotic twins. Cellular studies of a lymphoblastoid cell line
obtained from an affected patient demonstrated morphological abnormalities of the actin cytoskeleton and altered
actin depolymerization dynamics in response to latrunculin A, an actin monomer–sequestering drug. Resistance to
latrunculin A was also observed in NIH 3T3 cells expressing the mutant actin. These ﬁndings suggest that mutations
in nonmuscle actins may be associated with a broad spectrum of developmental malformations and/or neurological
abnormalities such as dystonia.
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Actin, one of the major cytoskeletal proteins, partici-
pates in many important cellular functions, including
muscle contraction, cell motility, cytokinesis, vesicle and
organelle movement, cell signaling, and the establish-
ment and maintenance of cell junctions and cell shape.1–
5 It is highly conserved throughout evolution because it
interacts with a large number of proteins.1 The actin
family comprises three major isoform groups based on
electrophoretic mobility: a-actin, b-actin, and g-actin.6
In mammalian cells, there are six isoforms coded by
separate genes, consisting of four muscle isoforms (a-
skeletal, aortic smooth, cardiac, and g2-enteric) and two
nonmuscle actins (b and g1).7Whereas cellular actinmay
be altered in various disease states and in aging,8–10 160
mutations of the skeletal (ACTA1) and cardiac (ACTC)
muscle actin genes have been identiﬁed in hereditary
muscle diseases.11–13 The majority of ACTA1 mutations
are dominant, a small number are recessive, and most
isolated cases in individuals with no previous family his-
tory are de novo dominant mutations.11 In contrast, re-
ports of nonmuscle actin mutations have been limited
to two reports of the g-actin gene (ACTG1) in familial
deafness14,15 and the b-actin gene (ACTB) in a single
patient with recurrent infections.16 However, no neu-
rodegenerative syndromes or ventral midline–defect phe-
notypes have been linked to mutations in vertebrate non-
muscle actin genes.
Dystonia is a movement disorder syndrome charac-
terized by sustained involuntary muscle contractions
that cause abnormal postures and repetitive move-
ments.17,18 To date, genetic loci have been identiﬁed in
at least 12 autosomal dominant forms, and the speciﬁc
disease genes have been identiﬁed in 5 autosomal dom-
inant forms, in 1 X-linked form, and in 1 autosomal
recessive form.19 Here, we report that a mutation in the
nonmuscle isoform ACTB is associated with a combi-
nation of ventral midline malformations, sensory hear-
ing loss, and delayed-onset generalized dystonia.
Material and Methods
Patient Tissues and Cell Lines
The neuropathology of the probands was reported else-
where.20 At the time of the brain autopsy, tissue samples were
frozen immediately on metal plates previously cooled in a
80C freezer. The frozen samples were then stored at80C.
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Table 1
Primer Sequences for the ACTB Gene and for ACTB,
ACTG1, CFL1, and ADF cDNAs
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
The remainder of the brain tissue was ﬁxed in neutral buffered
formalin at room temperature, sections were taken for parafﬁn
embedding, and the remaining formalin-ﬁxed tissue was stored
in sealed plastic bags at room temperature. Between the deaths
of the ﬁrst and second probands, blood samples were obtained
with informed consent from the surviving proband, themother,
and the two half-brothers. Buffy coat fractions were obtained
and transformed using Epstein-Barr virus, in accordance with
standard published procedures.21 Lymphoblastoid cell lines
from the patient, ﬁrst-degree relatives, and controls were pas-
saged in RPMI 1640 supplemented with additional glucose
(ﬁnal concentration 4.5 mg/ml), 10% fetal bovine serum, 50
mg/ml uridine, and 1 mM pyruvate.
DNA Sequencing and Mutation Analysis
DNA was extracted from brain tissues, cell lines, and blood
samples with the use of a Puregene kit (Gentra Systems). Total
RNA was extracted from brain tissue and lymphoblast cell
lines with the use of TRIzol, was treated with DNAse I, was
puriﬁed using a RNAeasy kit (Qiagen), and was reverse tran-
scribed using a ﬁrst-strand cDNA kit (Invitrogen).
The ACTB gene (GenBank accession number M10277),
ACTB cDNA (GenBank accession number NM_001101),
ACTG1 cDNA (GenBank accession number NM_001614),
coﬁlin 1 (CFL1) cDNA (GenBank accession number NM_
005507), and actin depolymerizing factor (ADF) cDNA
(GenBank accession number NM_006870) were ampliﬁed us-
ing standard conditions and were sequenced with primers cho-
sen from the cDNA or genomic DNA reference sequences (ta-
ble 1). PCR products were treated with ExoSAP-IT (Amer-
sham), to remove primers and unincorporated nucleotides be-
fore sequencing. Sequencing reactions were performedwith the
ABI PRISM Big Dye Terminator Cycle Sequencing v3.0 Ready
Reaction Kit and were analyzed on an ABI 3100 DNA Ana-
lyzer (Applied Biosystems). To identify single polymorphisms
occurring in normal controls, we sequenced exon 4 of ACTB
in 117 DNA samples derived from unrelated control individ-
uals, of the same ethnicity as the patient, who had no neu-
rological or malformation disorders.
The patients were previously screened for torsion dystonia-
1 (DYT1) gene mutations as well as for the dystonia/deafness-
1 (DDP1) mutation, and the results were negative.20 Results
from mitochondrial respiration studies performed after muscle
biopsies were negative as well. The patients also exhibited
clinical features found in Opitz syndrome (OS [MIM300000]),
including ventral midline abnormalities such as esophageal
motility problems and hypertelorism. We therefore screened
for genetic abnormalities known to be associated with this
syndrome.22 The nine coding exons of the MID1 gene were
ampliﬁed using primers and conditions described elsewhere to
evaluate the X-linked form of the syndrome.23,24 To evaluate
the chromosome 22–linked form of the syndrome,25 FISH anal-
ysis was performed on metaphase lymphoblastoid cells from
the patient, with the use of the N25 and TUPLE1 probes
(Appligene Oncor) in accordance with the manufacturer’s
instructions.
Electrophoresis/Immunoblotting
Brain tissues stored at80Cwere pulverized in the presence
of liquid nitrogen before homogenization. Lymphoblasts were
harvested and were washed twice with PBS, and the cell pellets
were stored frozen at 80C. They were lysed in 3–4 vol of
SDS sample buffer (2% SDS, 80 mM Tris, 5% b-mercapto-
ethanol, 15% glycerol, and 0.05% bromophenol blue [pH
6.8]), were heated at 97C for 2 min, were homogenized by
brief sonication, and were heated again at 97C for 2 min.
Protein concentrations of the lysates were determined by a ﬁlter
paper dye-binding assay.26 For one-dimensional SDS-PAGE,
the lysates were used directly for analysis. Samples were load-
ed into the gel lanes in equal protein concentrations, with an
additional lane employed as a “loading control” (probed for
tubulin). For two-dimensional electrophoresis, proteins in the
lysates were precipitated by the method described elsewhere27
to remove SDS, were resuspended in isoelectric focusing (IEF)
sample buffer (8 M urea, 2% CHAPS, 50 mM dithiothreitol,
and 0.2% Bio-Lite 3/10 ampholytes) with brief sonication, and
were applied to pH 4–7 ReadyStrip immobilized pH gradient
(IPG) strips (11-cm gel [Bio-Rad]) by passive rehydration. IEF
was performed by applying 35,000 V/h, with a maximum volt-
age of 8,000 V, with the use of Protean IEF cell (Bio-Rad).
The IPG strips were equilibrated in equilibration buffer I (6
M urea, 0.375 M Tris-HCl [pH 8.8], 2% SDS, 20% glycerol,
and 2% dithiothreitol) for 10 min and then in equilibration
buffer II (6 M urea, 0.375 M Tris-HCl [pH 8.8], 2% SDS,
20% glycerol, and 2.5% iodoacetamide) for 10 min and were
applied to SDS-PAGE (12% acrylamide gel) for the second
dimension. The proteins from SDS-PAGE were transferred to
Immobilon-P (0.2 mm) membranes. After incubation in block-
ing solution (Tris-buffered saline [pH 7.4], 0.025% Triton X-
100, and 5% powdered milk), membranes were rinsed and
incubated overnight at 4C with either anti–b-actin (mouse
monoclonal clone AC-15 [Sigma]), anti–g-actin (sheep [Chem-
icon]), anti–pan-actin (mouse monoclonal clone AC-40
[Sigma]), or anti–a-tubulin (monoclonal mouse clone DMIA
[Sigma]). All antibodies were used in the 1:1,000–1:2,000 di-
lution range. After several rinses, the membranes were incu-
bated for 1 h at room temperature with appropriate horse-
radish peroxidase (HRP)–labeled secondary antibodies: HRP
goat anti-sheep (1:5,000 [Zymed]) and HRP donkey anti-
sheep IgG (1:7,000 [Jackson Immunoresearch Labs]). The
membranes were then rinsed, and proteins were visualized
using chemiluminescence (ECL [Amersham Biosciences]). The
x-ray ﬁlm was exposed to the membranes for varying time
intervals ranging from 5 s to 10 min. The developed ﬁlms
were scanned for image archiving and for densitometry
measurements.
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Coverslip Cultures/Phalloidin Staining and
Immunoﬂuorescence
Lymphoblast cell lines (sex- and age-matched control and
patient) were grown in RPMI 1640 supplemented with uridine
(5 mg/100 ml), gentamycin sulfate (0.05 mg/ml), and 20% fetal
bovine serum (Hyclone) in 25-cm2 ﬂasks under a 5% CO2
humidiﬁed incubator at 37C. Cells were seeded on coverslips
previously coated with the combination of 0.01% poly-L-ly-
sine (Sigma) and 20 mg/well of ﬁbronectin (Invitrogen) in
growth medium. After 24 h in culture, cells were incubated
for 24 h in medium containing 1% bovine growth serum. They
were then treated for 3 h with or without 0.25 mg/ml latrun-
culin A (Molecular Probes). Cells were then ﬁxed for 20 min
in 4% paraformaldehyde (PFA) in PBS, were permeabilized for
5 min in 0.1% Triton X-100 in PBS, and were processed for
visualization of ﬁlamentous actin with the use of Alexa Fluor
488 conjugated phalloidin (1:100 [Molecular Probes]),28 or
tetramethylrhodamine-phalloidin (Sigma) at 0.1 mg/ml. The
samples were mounted with Fluoromount (Fisher) and were
examined on a Zeiss microscope equipped with a 100# ob-
jective. Images were directly captured and were transferred to
Adobe Photoshop CS for printing.
For immunoﬂuorescence, coverslip cultures were ﬁxed either
with PFA, as described above, or with ice-cold methanol for
10 min. After rinsing and permeabilization, cells were incu-
bated with antibodies to either b-actin (AC-15, 1:1,000 di-
lution [Sigma]) or g-actin (sheep, 1:7,000 dilution [Chemicon])
for 1 h at room temperature. Coverslips were then rinsed and
were stained with appropriate secondary antibodies (Alexa
Fluor 488 goat anti-mouse IgG, 1:5,000 dilution; Alexa Fluor
568 donkey anti-sheep IgG, 1:5,000 dilution [Molecular
Probes]) for 1 h at room temperature. The coverslips were then
rinsed and mounted. The slides were examined in a LeicaDMR
microscope, and images were captured with a digital camera
and a Zeiss LSM50 confocal microscope. Images were pro-
cessed using Adobe Photoshop and Zeiss LSM software.
Flow Cytometry
Lymphoblast cell lines (control and patient) were treated
with and without latrunculin A for 15 min at 37C, were rinsed
in PBS, and were ﬁxed in 4% PFA for 20 min. After permea-
bilization in 0.025% Triton X-100 in PBS, cells were incubated
with Alexa Fluor 488 phalloidin for 30 min at 37C and were
resuspended in PBS. Actin ﬁlaments stained with phalloidin
were analyzed using an analytical ﬂow-cytometry system (BD
Biosciences). The results were analyzed using Flojo version 6.0
(Treestar).
Latrunculin A Studies on Transfected 3T3 cells
To verify that the R183W mutation in the patient lympho-
blasts was responsible for the resistance to latrunculin A, we
performed similar studies using NIH 3T3 cells stably trans-
fected with green ﬂuorescent protein (GFP)–tagged constructs
of mutant and wild-type b-actin. A cDNA construct encoding
full-length human b-actin was generated by RT-PCR and was
introduced into a plasmid pEGFP vector (BD Biosciences). Ex-
pression of the R183W substitution in the b-actin construct
was introduced by site-directed mutagenesis, with use of the
QuikChange XL Site-Directed Mutagenesis Kit (Stratagene)
with a pEGFP vector as a template plasmid harboring the entire
coding sequence of b-actin. Clones were conﬁrmed to contain
the desired mutation by DNA sequence analysis. NIH 3T3
cells were transfected with the wild-type andmutant constructs
with the use of standard commercial reagents (Effectene [Qia-
gen]) and were grown in selection media containing the neo-
mycin analogue, G418. The transfected cells that survived se-
lection demonstrated ∼30% positivity for GFP ﬂuorescence
when examined under epiﬂuorescence. Populations of cells en-
riched (180%) for efﬁcient transgene expression were obtained
using preparative ﬂuorescence-activated cell sorting at the Yer-
kes Primate Facility at Emory. The sensitivity of transfected
cells to the depolymerizing actions of latrunculin A was ini-
tially evaluated on live cell preparations with the use of con-
focal microscopy. Brieﬂy, the cells were plated at low density
onto chambers containing glass-bottomed wells that had been
previously coated with growth-factor–free commercial sub-
stratum (Matrigel) and were allowed to attach for 3 h. After
attachment, the mediumwas replaced with low-serummedium
(1%), and cells were allowed to incubate overnight. Chambers
were then rinsed, the medium was replaced with phenol-free
medium plus Hepes buffer, and they were placed on the stage
of an inverted Zeiss LSM 510 confocal microscope system,
which was ﬁtted with an objective warming collar and used
immersion oil designed for the warming environment. Micro-
scopic ﬁelds containing GFP ﬂuorescence associated with the
actin stress-ﬁber networks were selected using a 40# oil ob-
jective, and several pre-drug images were captured. Latrun-
culin A was then added to the chambers for ﬁnal concentra-
tions of either 250 or 500 ng/ml, and the ﬁelds were scanned
at intervals of 1 min, for up to 30 min. Image series were then
evaluated using LSM software. Control chambers in which no
drug was added demonstrated that the stress ﬁber–associated
ﬂuorescence remained stable over the 30-min incubation pe-
riod. On the basis of an examination of the real-time images,
quantitative experiments were performed on duplicate cov-
erslip cultures of the transfected cells with the use of a ﬁnal
latrunculin A concentration of 250 ng/ml. Coverslips were
rinsed and were ﬁxed with ice-cold methanol at intervals of
5, 10, 15, and 20 min after drug addition. Coverslip cultures
without drug treatment were included as controls. All pro-
cessed coverslips were mounted onto glass microscope slides
with the use of gelvatol and were examined using the Zeiss
LSM 510 confocal microscope. For each coverslip, ﬁve random
ﬁelds of cells were scanned using a 40# oil objective, and the
images were analyzed using Metamorph software to compute
the ﬂuorescence intensity of individual cell proﬁles as a per-
centage of cell area. The collected data was analyzed sta-
tistically with the use of the Student t test.
Results
Genetic Studies
The probands whomwe reported elsewhere were born
with several ventral midline malformations, including
cleft palate and lip, hypertelorism, and esophageal mo-
tility problems.20 The hearing loss was ﬁrst reported in
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Figure 1 FISH analysis of metaphase lymphoblast cells from the
proband, with DiGeorge markers for chromosome 22. The legend is
available in its entirety in the online version of The American Journal
of Human Genetics.
primary school, was documented by audiometric testing,
and was conﬁrmed through periodic follow-up by oto-
laryngological specialists. The hearing loss was severe
and bilateral, eventually necessitating the use of sign
language to communicate. Beginning in early adoles-
cence, the patients developed a progressive generalized
dystonia syndrome that led to death in their early twen-
ties due to repeated episodes of aspiration pneumonia.
As reported elsewhere, genetic testing results for DYT1
mutations associated with one of the forms of primary
dystonia18 were negative, as were results for the DDP1
mutation and known mitochondrial disorders.20 The
constellation of malformations exhibited by the patients
resembles OS.22 We searched for mutations in MID1,
the gene responsible for the X-linked form of OS
(XLOS),23 and found no mutations in the nine coding
and splice-site regions of this gene (data not shown). OS
is genetically heterogeneous, and an autosomal domi-
nant form (ADOS) has also been identiﬁed. Although
the gene implicated has not been discovered yet, ADOS
has been mapped to chromosome 22.22 Patients with
ADOS usually show a large chromosomal deletion in
the long arm of chromosome 22—in particular, in the
DiGeorge region (22q11.2).25 For this reason, we per-
formed FISH analysis with the use of two different
probes for the 22q11.2 region on lymphoblastoid cells
of the proband. Both probes revealed that no large de-
letions are present in the patient cells (ﬁg. 1).
Postmortem brain examinations of both patients re-
vealed a remarkable pathology consisting of abundant
proteinaceous inclusions that stained positively for actin
and for the actin regulatory protein, coﬁlin.20 Therefore,
genes coding for actin and actin regulatory proteins, such
as ADF and CFL1, were sequenced using cDNAs ob-
tained from reverse-transcribed mRNA from the brains
of both twins and from the lymphoblast cell line of the
second twin (table 1). A heterozygous missense point
mutation was identiﬁed in ACTB, which was conﬁrmed
by sequencing genomic DNA. As illustrated in ﬁg. 2A,
a sequence electrophoregram of the genomic sequence
from exon 4 identiﬁed a heterozygous base change of
cytosine to thymine at nucleotide position 547CrT. This
change predicts an amino acid substitution of arginine
(R) to tryptophan (W) at position 183 in the b-actin
molecule (R183W), which is highly conserved across
species (ﬁg. 2B). No mutations were identiﬁed in the
remaining ﬁve ACTB exons, in ACTG1, or in ADF and
CFL1 cDNAs (table 1). Similarly, no mutations inACTB
or other related genes were identiﬁed in the mother and
the two half brothers. Paternal samples were not avail-
able for analysis, but there is no paternal family history
of similar disorders. The patients had the appearance of
identical twins, and we have conﬁrmed monozygosity
with DNA microsatellite analysis, by typing a series of
polymorphic loci (ﬁg. 3A). In addition, a series of mi-
crosatellite markers in close proximity toACTB on chro-
mosome 7 was used to trace the inheritance of ACTB
alleles over generations. Individuals were genotyped for
markers on chromosome 7 bracketing the disease locus.
Segregation analysis of microsatellite markers ﬂanking
ACTB demonstrates the inheritance of maternal chro-
mosomes in the affected twins and an unaffected half
brother (ﬁg. 3B).
Mutations in skeletal muscle a-actin at this same po-
sition, R183, with different amino acid substitutions,
cysteine or glycine, are associated with severe myopa-
thies.11 In addition, a double mutant—R183A-D184A,
which does not confer an obvious cytopathic phenotype
in yeast29—was shown to induce resistance to the actin
depolymerizing agent, latrunculin A, both in yeast30 and
in mammalian cells.31 The 547CrT substitution was not
detected in sequence analysis of exon 4 of ACTB in 117
DNA control samples from a population of the same
ethnicity. Similarly, the R183W substitution was not
found in searches of databases reporting known poly-
morphisms in ACTB (dbSNP). These results argue
against the possibility that the R183W substitution rep-
resents a genetic polymorphism.
Biochemical Studies
The R183W substitution predicts a gene product with
a more acidic isoelectric point than its wild-type coun-
terpart. To test this hypothesis, we investigated the ex-
pression of mutant versus wild-type protein in brain and
lymphoblast cell lysate samples, using two-dimensional
gel electrophoresis and immunoblot analysis. As illus-
trated in ﬁgure 4A, wild-type b- and g-actin migrate
according to predicted isoelectric points (pI) of 5.29 and
5.31, respectively (Expasy Proteomics Server), and amo-
lecular size of 42 kDa. In cortical brain specimens from
both patients, a second, more acidic b-actin species with
a predicted pI of 5.21 was present at approximately
equal levels with wild-type. These ﬁndings are consistent
with the predicted R183W substitution. In contrast,
probing for g-actin revealed only the wild-type species.
Similarly, wild-type and mutant b-actin were detected in
the immunoblots from two-dimensional gels of lympho-
blastoid cell lysates from the second patient (ﬁg. 4B) but
not in those from a control sample or the mother. It has
been demonstrated elsewhere that the expression levels
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Figure 2 Identiﬁcation of the mutation in the gene coding for b-actin. A, Partial sequence of exon 4 of ACTB in a control, the patient,
and the patient’s mother. The sequences illustrated in the control and mother are no different than the sequence found in 117 ethnicity-matched
control samples of this region of the gene and in the two half-brothers. The patient shows a heterozygous CGG-to-TGG transition, which
predicts an R183W substitution. B, Sequence conservation of the b-actin sequence among different species. Alignment of amino acid sequences
in the region of the identiﬁed R183W substitution indicates the strict conservation of an arginine residue at position 183 in all species assessed,
from yeast to man.
Figure 3 Microsatellite analysis of proband family pedigree, to
determine monozygosity of probands with the use of random chro-
mosome microsatellite markers and markers for chromosome 7. The
legend is available in its entirety in the online version of The American
Journal of Human Genetics.
of actin pools are autoregulated, even in the presence
of mutant actin species.32,33 We therefore examined
whether our newly identiﬁed mutation would behave
similarly. Brain samples and cell lysates were subjected
to SDS-PAGE and immunoblot analysis probing for
b-, g-, and total actin, with the use of an antibody rec-
ognizing all isoform species. We observed no apparent
difference in the expression levels of these markers in
patient versus control samples (ﬁg. 4C and 4D). Den-
sitometric measurements of band intensity did not show
any differences (data not shown). These ﬁndings sug-
gest that the R183W substitution does not alter b-actin
stability or induce compensatory changes in the ex-
pression of other actin isoforms.
Morphological Studies
The morphology of the lymphoblastoid cell lines was
examined using both brightﬁeld microscopy, phalloidin
staining, and immunoﬂuorescence of actin isoforms.
Control cells exhibited a rounded morphology and la-
mellapodia with microspikes, as well as some small ﬁl-
opodia (ﬁg. 5A), and the pattern of ﬁlamentous actin
was most concentrated in the cell cortex (ﬁg. 5B). In
contrast, cells expressing the mutant b-actin exhibited
variations in cell shape, with long tapering processes
extending for distances greater than a cell diameter (ﬁg.
5C and 5D). Immunoﬂuorescence for b- and g-actin and
merged images (ﬁg. 5E–5G for control cells and ﬁg. 5H–
5J for patient cells) revealed the same differences in cell
morphology in the patient cells. In both wild-type and
mutant cells, the actin visualization was most intense at
the cell cortex, and the relative ﬂuorescence intensities
were similar for b- and g-actin, exhibiting a strong co-
localization pattern.
Molecular Modeling and Interactions with Phalloidin
versus Latrunculin A
The structural effect of the R183W substitution was
examined by modeling the mutation in known actin
structures. Furthermore, we used previous mutational
analyses on the binding of actin-disrupting drugs, to test
predictions of the R183W model. A molecular model of
the b-actin monomer region containing residue 183,
based on the crystal structure from C. elegans34 (ﬁg. 6A),
illustrates the arginine residue (183) positioned directly
across from the ATP-binding pocket. This residue can
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Figure 4 Two-dimensional and SDS-PAGE gel-immunoblot analyses of b- and g-actins in brain samples and cell lysates. A, Immunoblots
from two-dimensional gels probed for b- and g-actin in brain samples from an age-matched control and both patients. B, Immunoblots from
two-dimensional gels probed for b- and g-actin in lymphoblast cell lysates from an age-matched control, patient 2, and the patient’s mother.
C and D, Brain samples from both patients and cell lysate from the second patient, in which two species of b-actin are present in equal amounts,
consistent with heterozygosity. The theoretical pIs for wild-type and mutant b-actin (R183W) are 5.29 and 5.21 (Expasy). Only wild-type g-
actin with a theoretical pI of 5.31 was detected in brain and cell lysates from all individuals. Immunoblots are shown from SDS-PAGE analysis
of brain samples (C) and cell lysates (D) from controls, patients, and mother. The relative levels of b- versus g- and total actin did not show
any differences between controls, mother, and patients in the samples tested. All gel lanes were loaded with equal protein concentrations, and
a-tubulin was probed as a protein loading control.
potentially participate in a hydrogen-bonded network
with water molecules and Ser14/His73, which can form
a ﬂexible gatelike structure facilitating ATP exchange
within the cleft.35 The R183W substitution (ﬁg. 6B)
could theoretically disrupt the hydrogen bonds by in-
troducing the hydrophobic tryptophan side chain. Such
a change could potentially alter the ATP-binding pocket
without affecting the overall structure (ﬁg. 7). We pre-
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Figure 5 Brightﬁeld microscopy, phalloidin staining, and immunoﬂuorescence for b- and g-actins in patient and control lymphoblastoid
cell lines. Brightﬁeld phase-contrast images of control (A) and patient (C) lymphoblasts illustrate the rounded morphology with lamellapodia
and microspikes observed in control cells, in contrast to the extensive process formation observed in many of the patient cells. Epiﬂuorescence
images of Alexa Fluor 488 phalloidin staining in the same cells from control and patient illustrate actin-rich microspikes in the control cells
(B) and actin ﬁlaments in long ﬁlopodial processes in the patient cells (D). Immunoﬂuorescence confocal images of control cells stained for b-
actin (E, green) and g-actin (F, red). Both actin species are enriched in cortical regions and within microspikes and short ﬁlopodia (G, merged
images). Immunoﬂuorescence confocal images of a patient cell stained for b-actin (H, green) and g-actin (I, red). Both actin species are enriched
in cortical regions and within long ﬁlopodial processes (J, merged images). All cells were viewed with a 100# oil objective.
dicted from the model that the binding of drugs whose
recognition sites lie away from this region should remain
unaffected. Phalloidin binds to a site on subdomain III
and stabilizes actin ﬁlaments. The phalloidin-bindingdo-
main is removed from the ATP pocket (ﬁg. 7). To test
our prediction, we performed quantitative ﬂow-cyto-
metry analysis to determine the binding of Alexa-labeled
phalloidin to ﬁxed control and patient lymphoblasts and
found no differences (ﬁg. 6C and 6D).
In contrast to normal phalloidin binding, the R183W
substitution modiﬁed the response of cells to actinmono-
mer–sequestering drug latrunculin A, which binds close
to the ATP-pocket36,37 (ﬁg. 7). Microscopic analysis of
lymphoblasts treated with latrunculin A revealed that
drug conditions leading to the depolymerization of the
actin cytoskeleton in control lymphoblasts were less ef-
fective in cells carrying the R183W substitution (ﬁg. 8).
To assess this apparent resistance quantitatively, we
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Figure 6 Molecular models of wild-type versus mutant actin and of phalloidin binding. A, Structure of globular actin monomer based
on the crystal structure of actin from C. elegans (ACT1/3),34 viewed using Deepview/Swiss PDB viewer (PDB accession number 1D4X). The
ATP pocket region is magniﬁed, and arginine 183 (light blue) lies directly across from the ATP-binding pocket. (see ﬁg. 7 for an illustration of
the entire monomer). B, R183W substitution disrupting the hydrogen-bonding network across the ATP-binding pocket of C. elegans actin. In
addition, the tryptophan residue leads to a signiﬁcant loss in ﬂexibility of the residue. The most favorable rotamer predicted by the software
is shown. C, Representative results of ﬂow-cytometry measurements of phalloidin binding. Lymphoblast cell lines (control and patient) were
ﬁxed in PFA, were stained with phalloidin for 30 min at 37C, and were analyzed by ﬂow cytometry. No differences in actin ﬁlaments stained
with phalloidin were observed between control and patient cells. NSp Fluorescence-background control samples where phalloidin was omitted.
D, Analysis of the mean  SD phalloidin binding for control (1,385 138) and patient (1,349 191) cell lines. and in threeP p .8 np 10t
independent experiments.
treated the cells in suspension and measured the loss of
phalloidin-stained ﬁlamentous actin, using ﬂow cyto-
metry. Consistent with the microscopy results, the mu-
tant lymphoblasts were resistant to latrunculin A over
a wide range of drug concentrations (ﬁg. 9A and 9B).
In contrast, when the drug was washed out, actin re-
polymerized to the same baseline levels in both control
and mutant cells, irrespective of the extent of the la-
www.ajhg.org The American Journal of Human Genetics Volume 78 June 2006 955
Figure 7 Structure of globular actin monomer. The legend is
available in its entirety in the online version of The American Journal
of Human Genetics.
Figure 8 Effects of latrunculin A on attached mutant and control lymphoblasts. Control and patient lymphoblastoid cells were grown
on coverslips in serum-deprived media and were treated with 250 ng/ml latrunculin A for 3 h. Treatment of control cells resulted in complete
loss of ﬁlamentous actin visualized with Alexa Fluor 488 phalloidin staining. In contrast, ﬁlamentous actin is still present on patient cells after
drug treatment.
trunculin-induced actin depolymerization (ﬁg. 9C and
9D).
Resistance to Latrunculin A in Transfected 3T3 cells
Although the results of latrunculin A experiments per-
formed using patient lymphoblastoid cells suggest that
the R183W mutation was responsible for the resistance
observed, it is also possible that nonspeciﬁc effects of
the immortalization procedure may also have been re-
sponsible for the phenotype observed. In addition, it is
possible that the affected twins harbor additional genetic
abnormalities contributing to the phenotype, which has
been documented in some cases of myoclonus-dys-
tonia.38 To test whether latrunculin A resistance in our
patient lymphoblasts is a direct effect of the mutant b-
actin expression, we prepared GFP-tagged constructs of
wild-type and R183W b-actin and expressed them in
NIH 3T3 cells. Latrunculin A sensitivity was then eval-
uated qualitatively on living cell cultures and quantita-
tively onmethanol-ﬁxed coverslip cultures. As illustrated
in ﬁgure 10A, cells transfected with either the wild-type
or R183W construct did not show any distinct differ-
ences in the morphology of their respective b-actin stress-
ﬁber networks. However, after incubation in the pres-
ence of 250 ng/ml concentrations of latrunculin A, cells
transfected with the wild-type constructs demonstrated
stress-ﬁber loss by 15 min, whereas R183W-transfected
cells were less altered. By 30 min, substantial stress-ﬁber
loss was observed in the R183W-transfected cells, but
the response was still less striking than that in cells trans-
fected with the constructs (data not shown). At a higher
latrunculin A dose, 500 ng/ml, cells expressing the mu-
tant construct exhibited a faster loss of stress ﬁbers but
could still be distinguished from the wild-type cells (data
not shown).
Latrunculin A resistance was examined quantitatively
using coverslip cultures from either wild-type– or R183W-
transfected 3T3 cells, which were treated for varying
times with 250 ng/ml latrunculin A. As shown in ﬁgure
10B, cells transfected with the mutant construct exhib-
ited resistance to the depolymerizing actions of the drug
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Figure 9 Quantitation of latrunculin A resistance in patient cells using ﬂow cytometry. A and B, Both control and patient cells show
similar actin ﬁlament content in nontreated cells. Latrunculin A treatment (80 ng/ml) induces a rapid actin depolymerization in control compared
with patient cells. Actin ﬁlament content was reduced to 17%  1.8% and 50%  4.9% (average  SD, ) in control and patient,np 8
respectively. NS p Fluorescence-background control samples where phalloidin was omitted. B, Resistance of actin ﬁlaments in patient cells to
depolymerization also observed by using increasing concentrations of latrunculin A. C and D, Recovery from latrunculin A. Cells were treated
with 80 ng/ml of latrunculin A for 15 min, were washed, and were incubated with RPMI plus 10% fetal bovine serum for 5 min at 37C (C).
Cells were treated with 250 ng/ml latrunculin A for 30 min, were washed, and were incubated with RPMI plus 5% fetal bovine serum (D).
Under both conditions, actin ﬁlament content recovered to 100% in both control and patient cells.
at 10 min ( ), at 15 min ( ), and at 20P p .02 P ! .0001t t
min ( ). These results demonstrate that the mu-P p .04t
tant actin species is responsible for the cellular
phenotype.
Discussion
The results of the present studies indicate that amutation
in one of the major forms of nonmuscle actin, b-actin
(R183W), is associated with a complicated disease phe-
notype that includes developmental malformations, sen-
sory hearing loss, and a delayed-onset dystonia. To date,
reports of diseases resulting from alterations of non-
muscle actins have been extremely uncommon. For b-
actin, there is one report in the literature of a child with
recurrent infections who exhibited a mutation at posi-
tion 364 resulting from a substitution of glutamic acid
to a lysine residue and causing defects in leukocyte func-
tion.16 In contrast to the location of the mutation that
we are reporting, the latter mutation was reported to
reside in an actin subregion that is important for proﬁlin
binding, which facilitates nucleotide exchangewithin the
actin monomer.39
In the present study, the R183W substitution replaces
a ﬂexible arginine residue with a more rigid hydrophobic
tryptophan. Both database searches and testing of our
own control samples failed to reveal this substitution as
a polymorphism. In addition, the arginine residue at po-
sition 183 is highly conserved throughout species (ﬁg.
2B). This point is further supported by observations
demonstrating that mutations at the same position 183
with different amino acid substitutions, such as cysteine
Figure 10 Latrunculin A resistance in NIH 3T3 cells expressing a GFP-tagged construct of R183W actin, compared with cells expressing
a wild-type construct. A, Real-time confocal images of GFP-ﬂuorescing wild-type (WT) and mutant (Mut) transfected cells before and 15 min
after addition of latrunculin A (Lat) to a ﬁnal concentration of 250 ng/ml. Note the loss of the stress-ﬁber network in the WT cells (top left
vs. top right panels), in contrast to lack of signiﬁcant change of stress ﬁbers in the Mut cells (bottom left vs. bottom right panels). The images
are representative of two separate experiments and a total of seven chamber cultures of WT cells and eight chamber cultures of Mut cells. The
images were scanned under a 40# oil objective. B, Quantitation of stress-ﬁber depolymerization in Mut versus WT coverslip cultures after
incubation in the presence of 250 ng/ml latrunculin A for 10, 15, and 20 min. At each type point, the coverslips were rapidly rinsed and were
ﬁxed with methanol at 20C. Confocal image series were captured from ﬁve random ﬁelds from each coverslip using a 40# oil objective and
Zeiss LSM software. LSM series were converted to TIFF ﬁles, and individual cells were analyzed for the percentage of cell area containing
ﬂuorescence with the use of Metamorph software. Image analysis for each series was performed on optical sections containing optimal visu-
alization of the stress-ﬁber network. The results are from a single experiment performed using duplicate coverslips (a total of 10 ﬁelds) for each
time point. ND indicates control coverslips without drug treatment. The numbers above the columns represent the cell number analyzed. Pt
are .02 at 10 min, !.0001 at 15 min, and .04 at 20 min.
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or glycine, have been documented in ACTA1, all of
which result in severe myopathies.11 These mutations
exert a dominant-negative effect, which supports the
concept of a “poison” protein rather than a decrease of
normal actin function.40 More than 60 mutations of
ACTA1 have been identiﬁed to date and are associated
with three categories of muscle disease: (1) actin my-
opathy, (2) nemaline myopathy, and (3) intranuclear rod
myopathy.11,13,40,41 The characterization of these muta-
tions in ACTA1, coupled with structural and functional
studies of a-actin, has provided insights into genotypic-
phenotypic distinctions and correlations between these
different hereditary myopathies.42
The results of the present studies indicate that the
R183W substitution affects actin dynamics in the patient
lymphoblast cells and in a cell line expressing the mutant
actin, and they suggest potential mechanisms by which
the mutant actin form may alter the actin cytoskeletal
architecture and function. First, the mutation may affect
the integrity and function of the ATP-binding pocket or
regions close to the pocket that are known to bind la-
trunculin A. Alternatively, the R183W substitution may
confer greater rigidity to the ﬁlamentous molecule with
lowered depolymerization dynamics. This hypothesis
would explain the presence of coﬁlin-decorated actin
inclusions in the brains of both patients.20 Coﬁlin facil-
itates depolymerization by binding preferentially to ade-
nosine diphosphate–rich actin ﬁlaments.43 In vivo, the
generation of small actin oligomers increases actin nu-
cleation.44 If the mutant ﬁlaments are resistant to normal
physiologic depolymerization signals or to drugs that
lower the effective concentration of ATP monomer, as
with latrunculin A, then the accumulation of ﬁlamentous
inclusions would be expected. Since depolymerization is
the rate-limiting step in actin turnover and is critical for
many biological functions, it is reasonable to hypoth-
esize that the cellular abnormalities arising from the
present mutation are linked to this defect.
The prevalence of MZ twins affected with nemaline
myopathy has been reported to be higher than expected,
and it has been suggested that the presence of ACTA1
mutations might alter actin dynamics during early
phases of embryogenesis.45 In addition, our patients’
phenotypes shared some clinical similarities with OS de-
ﬁned by midline abnormalities such as cleft lip and pal-
ate, hypertelorism, and esophageal motility abnormali-
ties. Mutations in MID1, a member of the B-box protein
family encoding the protein midin, have been identiﬁed
in the X-linked form of OS, and these mutations have
been proposed to result in altered microtubule dynam-
ics.46 Interestingly, MZ twinning is unusually frequent
in these families and may be a consequence of analogous
developmental errors.45 Segregation analysis of micro-
satellite markers ﬂanking the ACTB gene on chromo-
some 7 of our cohort demonstrates the inheritance of
the same maternal alleles in the probands, which differs
from one of the half-brothers (ﬁg. 3B). On the basis of
studies of ACTA1 mutations, a large number of cases
are sporadic, arising as de novo dominant missense mu-
tations.11 A small number are either compound hetero-
zygous or recessive, and two families have been shown
to have somatic mosaicism for the mutation in one of
the parents.42 Unfortunately, we were not able to ex-
amine the father of our probands to rule out this
possibility.
In summary, we have identiﬁed a mutation in b-actin
that is associated with several disease phenotypes, in-
cluding a syndrome of ventral midline defects resembling
OS,47 sensory hearing loss, and delayed-onset general-
ized dystonia. The implications of these ﬁndings suggest
that genetic variants of nonmuscle actins may play a
wider role in human disease, analogous to the spectrum
of myopathic diseases that have been associated with
mutations in the muscle actin isoforms.41 In addition,
actin effects are probably mutation speciﬁc and reﬂect
the presence of different functional domains of the
monomer and ﬁlament. In fact, although numerous de-
velopmental malformation syndromes and hereditode-
generative diseases related to dystonia have been
mapped to speciﬁc chromosomal loci and genes, the vast
majority of these entities remain poorly understood.17,48
Given the important actions of b-actin in all cells, it is
not surprising to connect abnormalities of actin dynam-
ics with developmental as well as neurological disorders.
In fact, proteins that are known to function in concert
with actin have been implicated in hereditary disorders
and malformation syndromes, such as dynamin in Char-
cot-Marie-Tooth disease,49 ﬁlamin in otopalatodigital
syndromes,50 as well as other conditions.5 With respect
to neural-tube closure defects, it has recently been sug-
gested that actin abnormalities should be considered as
important candidates for uncovering new pathogenic
mechanisms.51 Ongoing studies are aimed at analyzing
the functional consequences of the b-actin mutation we
have identiﬁed, as well as others, which should help us
to understand the complex clinical phenotype of our
patients.
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